INTRODUCTION: The aim of this study was to investigate the incidence of second primary tumors in patients with breast cancer (BC), with particular regard to bidirectional risk for endometrial cancer (EC). METHODS: A total of 7512 and 343 patients with first and second primary BC, respectively, were referenced to the expected number of cases calculated using the standardized incidence ratio (SIR) over the same period, to evaluate the observed and expected ratio between the groups. Data on tamoxifen use were also considered. RESULTS: A total of 499 women with primary BC developed a second tumor. The total SIR, that is, the ratio between observed second primary cancer among patients with BC and the expected primary cancers in the general population, was significantly higher (SIR = 1.23; 95% confidence interval, 1.12-1.34; P = 0.007), particularly for melanoma (2.25), EC (2.15), ovarian cancer (1.74), hematologic malignancies (1.36), and bilateral BC (1.25). A greater risk of BC after thyroid (2.22) and EC (1.62) was also observed. Furthermore, the risk of developing EC was higher in patients treated with tamoxifen (SIR = 2.50 vs 1.34). CONCLUSIONS: Bidirectional risk of endometrial cancer was not exclusively related to tamoxifen use.

Distribution of second primari malignancies suggest a bidirectional effect between breast and endometrial cancer. A population-based study / Cortesi, L.; DE MATTEIS, Elisabetta; Rashid, I.; Cirilli, C.; Proietto, Manuela; Rivasi, Francesco; Federico, Massimo. - In: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. - ISSN 1048-891X. - ELETTRONICO. - 19 (8):(2009), pp. 1358-1363. [10.1111/IGC.0b013e3181b9f5d5]

Distribution of second primari malignancies suggest a bidirectional effect between breast and endometrial cancer. A population-based study

DE MATTEIS, Elisabetta;PROIETTO, Manuela;RIVASI, Francesco;FEDERICO, Massimo
2009

Abstract

INTRODUCTION: The aim of this study was to investigate the incidence of second primary tumors in patients with breast cancer (BC), with particular regard to bidirectional risk for endometrial cancer (EC). METHODS: A total of 7512 and 343 patients with first and second primary BC, respectively, were referenced to the expected number of cases calculated using the standardized incidence ratio (SIR) over the same period, to evaluate the observed and expected ratio between the groups. Data on tamoxifen use were also considered. RESULTS: A total of 499 women with primary BC developed a second tumor. The total SIR, that is, the ratio between observed second primary cancer among patients with BC and the expected primary cancers in the general population, was significantly higher (SIR = 1.23; 95% confidence interval, 1.12-1.34; P = 0.007), particularly for melanoma (2.25), EC (2.15), ovarian cancer (1.74), hematologic malignancies (1.36), and bilateral BC (1.25). A greater risk of BC after thyroid (2.22) and EC (1.62) was also observed. Furthermore, the risk of developing EC was higher in patients treated with tamoxifen (SIR = 2.50 vs 1.34). CONCLUSIONS: Bidirectional risk of endometrial cancer was not exclusively related to tamoxifen use.
2009
19 (8)
1358
1363
Distribution of second primari malignancies suggest a bidirectional effect between breast and endometrial cancer. A population-based study / Cortesi, L.; DE MATTEIS, Elisabetta; Rashid, I.; Cirilli, C.; Proietto, Manuela; Rivasi, Francesco; Federico, Massimo. - In: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. - ISSN 1048-891X. - ELETTRONICO. - 19 (8):(2009), pp. 1358-1363. [10.1111/IGC.0b013e3181b9f5d5]
Cortesi, L.; DE MATTEIS, Elisabetta; Rashid, I.; Cirilli, C.; Proietto, Manuela; Rivasi, Francesco; Federico, Massimo
File in questo prodotto:
File Dimensione Formato  
Distribution of second.....pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 548.21 kB
Formato Adobe PDF
548.21 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/631685
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 14
social impact